Last reviewed · How we verify
Chromax
Chromax is a Small molecule drug developed by Benha University. It is currently in Phase 2 development. Also known as: study Group.
Chromax, a form of chromium, has been studied in combination with other interventions for conditions including Polycystic Ovary Syndrome, Insulin Resistance, and Prostatic Hyperplasia. Specifically, it has been investigated as part of a combination treatment with myoinositol, l-arginine, and letrozole for ovulation induction in patients with Polycystic Ovarian Syndrome.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chromax |
|---|---|
| Also known as | study Group |
| Sponsor | Benha University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients (PHASE3)
- Evaluation of the Effect of Garcinia in Combination With Chromium on the Clinical Outcomes of Patients With LUTS/BPH (PHASE2)
- Novel Therapy for Glucose Intolerance in HIV Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chromax CI brief — competitive landscape report
- Chromax updates RSS · CI watch RSS
- Benha University portfolio CI
Frequently asked questions about Chromax
What is Chromax?
Who makes Chromax?
Is Chromax also known as anything else?
What development phase is Chromax in?
Related
- Manufacturer: Benha University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: study Group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing